Results 31 to 40 of about 4,828 (174)

Pulmonary Deposition of Radionucleotide-Labeled Palivizumab: Proof-of-Concept Study

Frontiers in Pharmacology, 2020
ObjectiveCurrent prevention and/or treatment options for respiratory syncytial virus (RSV) infections are limited as no vaccine is available. Prophylaxis with palivizumab is very expensive and requires multiple intramuscular injections over the RSV ...
Anushi E. Rajapaksa, Anushi E. Rajapaksa, Anushi E. Rajapaksa, Lien Anh Ha Do, Lien Anh Ha Do, Darren Suryawijaya Ong, Darren Suryawijaya Ong, Magdy Sourial, Duncan Veysey, Richard Beare, Richard Beare, William Hughes, William Yang, Robert J. Bischof, Robert J. Bischof, Amarin McDonnell, Peter Eu, Leslie Y. Yeo, Paul V. Licciardi, Paul V. Licciardi, Edward K. Mulholland, Edward K. Mulholland, Edward K. Mulholland   +22 more
doaj   +1 more source

Universal palivizumab prophylaxis for children with Down syndrome in Japan: analysis with interrupted time-series

Human Vaccines & Immunotherapeutics, 2021
Down syndrome (DS) is an independent risk factor for severe respiratory syncytial virus (RSV) infection. Palivizumab – passive immunization for RSV – is the only pharmacological measure for preventing severe disease.
Masato Takeuchi, Koji Kawakami
doaj   +1 more source

The Development of Global Genomic Surveillance of Respiratory Syncytial Virus: Insights From 25 Project Countries, 2019–2023

Influenza and Other Respiratory Viruses, Volume 20, Issue 3, March 2026.
ABSTRACT Background From 2016 to 2018, the World Health Organization (WHO) initiated a global RSV surveillance pilot program in 14 countries, expanding to 25 countries from 2019 to 2023. As part of this, a sequencing program was introduced to improve the understanding of RSV global genetic diversity prior to and following the introduction of ...
Obadiah Kenji, Fernando Motta, Thomas Williams, Nicole Wolter, Ian G. Barr, Clyde Dapat, Maria Zambon, Lucy Mosscrop, Mei Shang, Sergejs Nikisins, Siddhivinayak Hirve, Wenqing Zhang, the WHO RSV Surveillance Group   +12 more
wiley   +1 more source

Exacerbations and Management of Asthma in Viral Lower Respiratory Tract Infections: The Significance of Immunoglobulin E

Immunity, Inflammation and Disease, Volume 14, Issue 2, February 2026.
ABSTRACT Background Viral‐respiratory infections are the most prevalent illness among humans. A viral infection affecting lower respiratory tract infections (LRTI) is a critical health concern worldwide. The COVID‐19 pandemic has significantly impacted respiratory health, particularly in individuals with asthma.
Mandana Akhavan, Parastoo Yousefi, Alireza Tabibzadeh   +2 more
wiley   +1 more source

The Danish National Prescription Registry in studies of a biological pharmaceutical: palivizumab – validation against two external data sources

Clinical Epidemiology, 2015
Ann Haerskjold,1,2 Lonny Henriksen,2 Susanne Way,1 Mikkel Malham,3 Jesper Hallas,4 Lars Pedersen,5 Lone Graff Stensballe1 1The Child and Adolescent Clinic 4072, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark; 2The Research Unit Women&#
Haerskjold A, Henriksen L, Way S, Malham M, Hallas J, Pedersen L, Stensballe LG   +6 more
doaj  

Incidence of respiratory syncytial virus infection in children with congenital heart disease undergoing immunoprophylaxis with palivizumab in Pará state, north region of Brazil

BMC Pediatrics, 2019
Background Palivizumab prophylaxis for the human respiratory syncytial virus (HRSV) has been reported to reduce the risk of hospital admissions related to HRSV in children with congenital heart disease (CHD). These children are at high risk of developing
Roseane Porfírio de Souza, Andre Luis Ribeiro Ribeiro, Sílvio Augusto Fernandes de Menezes, Luiz Fernando Almeida Machado   +3 more
doaj   +1 more source

The Impact of Nirsevimab on Bronchiolitis‐Related Hospitalizations: A Multicenter Italian Retrospective Comparative Study

Pediatric Pulmonology, Volume 61, Issue 2, February 2026.
ABSTRACT Introduction Bronchiolitis is the leading cause of infant hospitalizations worldwide, primarily driven by respiratory syncytial virus (RSV). Methods This multicenter retrospective comparative study assessed the impact of immunoprophylaxis with nirsevimab against RSV on bronchiolitis‐related hospitalizations in Italy during the 2024–2025 winter
Sergio Ghirardo, Barbara Madini, Nicola Ullmann, Alessandro Zago, Michele Ghezzi, Enza D'Auria, Marta Minute, Stefano Martelossi, Anna Chiara Vittucci, Sebastian Cristaldi, Sara Procoli, Francesca Castelletti, Vincenzo Guaia, Alessia Rocchi, Beatrice Andrenacci, Francesco Maria Risso, Andrea Trombetta, Luca Barchi, Simone Foti Randazzese, Sara Manti, Eloisa Gitto, Virginia Mirra, Paolo Siani, S. Salvatore Aversa, Alessandro De Fanti, Maria Francesca Patria, Alessandro Amaddeo, Egidio Barbi, Renato Cutrera   +28 more
wiley   +1 more source

Scale‐up of a monoclonal antibody CHO fed‐batch production in stirred tank bioreactors: Effect of hydrodynamic conditions and feeding regimen

Biotechnology Progress, Volume 42, Issue 1, January/February 2026.
Abstract Key hydrodynamic‐related parameters such as volumetric power input (P/V), impeller configuration, aeration strategy, and maximum gas sparge rate, as well as an appropriate feeding strategy, must be carefully selected to improve production yields in bioreactor.
Lucas Lemire, Sebastian‐Juan Reyes, Yves Durocher, Robert Voyer, Olivier Henry, Phuong Lan Pham   +5 more
wiley   +1 more source

Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective

International Journal of Pediatrics, 2014
Infection with respiratory syncytial virus (RSV) is one of the major causes globally of childhood respiratory morbidity and hospitalization. Palivizumab, a humanized monoclonal antibody, has been recommended for high risk infants to prevent severe RSV ...
Nusrat Homaira, William Rawlinson, Thomas L. Snelling, Adam Jaffe   +3 more
doaj   +1 more source

Healthcare Utilization in Children Following Hospitalization for RSV‐ Versus Non‐RSV Related Lower Respiratory Tract Infections: A Nationwide Retrospective Study

Pediatric Pulmonology, Volume 61, Issue 1, January 2026.
ABSTRACT Introduction Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections (LRTIs) in young children. Additionally, RSV is associated with long‐term respiratory morbidities. This study evaluates acute and long‐term healthcare utilization (HCU) in infants hospitalized with RSV‐associated LRTI (RSV‐LRTI) compared to ...
Guy Hazan, Mai Ofri, Lital Hertz, Oliver Martyn, David Greenberg   +4 more
wiley   +1 more source